Tag Archives: Cadila Healthcare Ltd

Zydus Biologics (of Zydus Cadila Group) inspected successfully by US FDA

AHMEDABAD | MUMBAI | RAJKOT – In a press-release submitted to the Indian Bourses, Cadila Healthcare Ltd (Dr Pankaj Patel led Zydus Cadila Group) said of one of the company’s subsidiary facilities being inspected successfully by US Food & Drug Administration. The Company’s Biologics manufacturing facility (Zydus Biologics) located at the Zydus Biotech Park in

Zydus Cadila gets US FDA nod to market osteoporosis, ortho treatment drug

MUMBAI | AHMEDABAD | RAJKOT – Dr Pankaj Patel led and Ahmedabad headquartered Zydus Cadila Group (Cadila Healthcare Ltd) has received final approval from the US regulators to market ortho treatment medicine, the company said in a press release submitted to the Indian Bourses, today. Zydus Cadila has received the final approval from the USFDA

Zydus Cadila keen to set-up mfg facility at Hyderabad, reports Telangana Today

HYDERABAD | AHMEDABAD | RAJKOT – Ahmedabad headquartered and Dr Pankaj Patel led Zydus Cadila Group (Cadila Healthcare Ltd) is keen to establish setting-up a facility in the upcoming Hyderabad Pharma City, Telengana Today reports Quoting Dr Pankaj Patel as told to Telengana Today, the report said of Cadila Healthcare in future to surely look

Zydus Cadila gets US FDA nod to market tablets for diabetic care

AHMEDABAD | MUMBAI | RAJKOT – In a press release submitted to the Indian Bourses on Tuesday, Dr Pankaj Patel led Zydus Cadila group (Cadila Healthcare Ltd.) said of having got approval from US FDA (Food & Drugs Administration) to market Sitagliptin Tablets in dosage value of 25 mg (milligram), 50 mg and 100 mg.

Zydus Cadila gets USFDA nod to market anti-viral drug

AHMEDABAD | MUMBAI | RAJKOT – Dr Pankaj Patel led Zydus Cadila Group got US FDA (Food and Drugs Administration) nod to market anti-viral drug Acyclovir Sodium Injection in composition of 500 mg and 1,000 mg, Cadila Healthcare Ltd said today, in a press release submitted to the Exchanges in India. Zydus Cadila has received

Zydus Cadila to pay 1.56 billion rupees to acquires 51% stake in Windlass Healthcare

AHMEDABAD | MUMBAI | RAJKOT – Zydus Cadila Group will pay 1.55 billion (~155.55 crore) rupees to acquire 51% stake in Dehradun (Uttarakhand) headquartered Windlas Healthcare Pvt Ltd, the company press release submitted to the Exchanges in India on Monday read. The acquisition detailing regulatory document submitted to the exchange termed the objective of the

Zydus Cadila gets USFDA nod to market anti-bacterial drug to cure respiratory, skin, ear and sexually transmitted disease

AHMEDABAD | MUMBAI | RAJKOT – Zydus Cadila (Cadila Healthcare Ltd) has received the final approval from the USFDA to market Azithromycin for Oral Suspension USP (US RLD – Zithromax), 100 mg/5 mL and 200 mg/5 mL, the company said in the press release submitted to Exchanges in India on Wednesday. This medication contains Azithromycin, a

Zydus Cadila gets USFDA nod to market impotence treatment drug

AHMEDABAD | MUMBAI | RAJKOT – In a press release submitted to the exchanges in India, Cadila Healthcare Ltd said of having got tentative approval to market drug to cure erectile dysfunction. Zydus Cadila has received the tentative approval from the USFDA to market Vardenafil Hydrochloride Tablets (US RLD-Levitra) in the strengths of 2.5 mg, 5

Zydus Cadila gets USFDA nod to market injection to cure liver injury

AHMEDABAD | MUMBAI | RAJKOT – Cadila Healthcare Ltd in a regulatory filing submitted to the Exchanges in India said of having got US FDA (Food & Drug Administration) nod to market an injection to cure liver injury. Zydus Cadila has received the final approval from the USFDA to market Acetylcysteine Injection (US RLD –

Zydus Cadila cracks one more USFDA approval to cure High Blood Pressure

AHMEDABAD | MUMBAI | RAJKOT – In a regulatory filing submitted to exchanges in India on Friday, Cadila Healthcare Ltd said of getting one more approval from US FDA (Food & Drug Administration) to market tablets to cure high blood pressure and prevent heart failure. Zydus Cadila has received the final approval from the USFDA

USFDA Approvals raining for Zydus Cadila, clicks one more, to market joint-pain (arthritis) treatment drug

AHMEDABAD | MUMBAI | RAJKOT – It seems US FDA (Food & Drug Administration) approvals are raining for Zydus Cadila (Cadila Healthcare Ltd) as the company has been constantly submitting USFDA approval filings on one or the other day in the month of July. Zydus Cadila has one more to its portfolio and this time

Zydus Cadila gets USFDA nod to market four new drugs

AHMEDABAD | MUMBAI | RAJKOT – Zydus Cadila (Cadila Healthcare Ltd) got US FDA (Food & Drugs Administration) nod to market four drugs, this drugs are primely used to treat mental moods/conditions & depression, diet & exercise equivalent to cure diabetic disorders, injection to treat fungal infections and a drug to treat skin allergies, the

Zydus Cadila gets USFDA nod to market anti-migraine drug

AHMEDABAD | MUMBAI | RAJKOT – In a regulatory filing submitted to the Exchanges in India, Cadila Healthcare said of getting US FDA (Food & Drug Administration) approval to market anti-migraine drug Zolmitriptan. Zydus Cadila has received the final approval from the USFDA to market Zolmitriptan Tablets, 2.5 mg and 5 mg. It is used to

CSIR-IMTECH and Zydus Cadila shake-hands for development new drugs for drug-resistant infectious diseases

AHMEDABAD | MUMBAI | RAJKOT – The Council of Scientific and Industrial Research (CSIR) – Institute of Microbial Technology (IMTECH), a premier microbial institute under the aegis of the Ministry of Science and Technology, Government of India, recently signed a collaborative research agreement with Zydus Cadila , an innovation-driven global healthcare group, the company (Cadila

In just 3 days, Zydus Cadila gets USFDA nod for another hypertension (high blood pressure) treatment drug

AHMEDABAD | MUMBAI | RAJKOT – In a regulatory filing shot on the Indian bourses, Cadila Healthcare Ltd (Zydus Cadila) has informed of having received final approval from USFDA (US Food & Drug Administration)  to market Nifedipine Extended — Release Tablets USP and Cholestyramine for Oral Suspension USP. On June 30, 2018 – Saturday,  Cadila

Zydus Cadila gets USFDA nod for Hypertension (high blood pressure) treatment drug

AHMEDABAD | MUMBAI | RAJKOT – Zydus Cadila (Cadila Healthcare Ltd) has received the final approval from the USFDA (US Food & Drug Administration) to market Triamterene and Hydrochlorothiazide Tablets USP in strengths of 37.5 mg/25 mg and 75 mg/SO mg, the company said in a regulatory filing submitted to the Exchanges in India, on